KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) EPS (Basic) (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of EPS (Basic) data on record, last reported at $1.62 in Q4 2025.

  • For Q4 2025, EPS (Basic) rose 86.21% year-over-year to $1.62; the TTM value through Dec 2025 reached $2.32, up 69.34%, while the annual FY2025 figure was $2.32, 69.34% up from the prior year.
  • EPS (Basic) reached $1.62 in Q4 2025 per ACAD's latest filing, up from $0.43 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $1.62 in Q4 2025 and bottomed at -$0.7 in Q1 2022.
  • Average EPS (Basic) over 5 years is $0.05, with a median of -$0.04 recorded in 2021.
  • Peak YoY movement for EPS (Basic): plummeted 135.29% in 2023, then skyrocketed 1900.0% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at -$0.27 in 2021, then increased by 3.7% to -$0.26 in 2022, then surged by 207.69% to $0.28 in 2023, then soared by 210.71% to $0.87 in 2024, then soared by 86.21% to $1.62 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were $1.62 in Q4 2025, $0.43 in Q3 2025, and $0.16 in Q2 2025.